What is the revenue and EPS growth rate for Esperion year over year?

What guidance did Esperion's management provide for the next earnings period?

What is the market's earnings forecast for Esperion next quarter?

What does Esperion do and what are its main business segments?

Did Esperion beat or miss consensus estimates last quarter?

What is Esperion's latest dividend and current dividend yield?

What were the key takeaways from Esperion’s earnings call?

What is Esperion's gross profit margin?

- **Acquisition Boost**: Corstasis acquisition adds $4B+ heart failure market, with Enbumyst launch in Q2 2026 and subcutaneous pipeline potential.
- **Revenue Surge**: Q4 2025 U.S. net product revenue up 38%, Japan launch exceeds expectations, and collaboration revenue jumps 232%.
- **Pipeline Momentum**: ESP-2001 advancing for PSC; triple combo therapies target 70% LDL reduction with 2027 NDA filings.
- **Financial Strength**: $167.9M cash, debt reduced by $55M, and 2026 operating expenses guided at $225M-$255M.
- **Strategic Growth**: Vision 2040 focuses on bempedoic acid and Enbumyst franchises, with international expansion and pipeline innovation driving long-term value.

**【CEO Summary Section】**
- **Transformative Year**: 2025 marked Esperion's best year, driven by the acquisition of Corstasis Therapeutics, which adds Enbumyst (FDA-approved intranasal diuretic) and a subcutaneous pipeline. This expands Esperion's portfolio into heart failure, complementing its lipid management franchise.
- **Bempedoic Acid Franchise Growth**: Q4 2025 U.S. net product revenue grew 38% YoY, with retail prescription equivalents up 34%. Japan launch exceeded expectations, with NEXLETOL achieving a favorable NHI price listing.
- **Pipeline Progress**: ESP-2001, a next-gen ACLY inhibitor, is advancing for primary sclerosing cholangitis (PSC), with IND-enabling studies complete.
- **Strategic Initiatives**: Vision 2040 aims to grow bempedoic acid and Enbumyst into multibillion-dollar franchises. Triple combination therapies (bempedoic acid + ezetimibe + statin) target 70% LDL reduction, with potential NDA filings in 2027.

**【CFO Financial Commentary】**
- **Q4 2025 Financials**: Total revenue $168.4M (144% YoY growth), driven by $90M one-time payment from Otsuka. U.S. net product revenue $43.7M (38% YoY), collaboration revenue $124.7M (232% YoY). R&D expenses $13.9M (26% YoY), SG&A $41.4M (12% YoY).
- **Cash Position**: $167.9M in cash, supporting Enbumyst launch and debt reduction ($55M debt paid off in 2025).
- **2026 Guidance**: Operating expenses $225M-$255M, including $15M non-cash stock comp. Focus on cost control and collaboration revenue growth.

**【Q&A Highlights】**
- **Enbumyst Launch**: Expected Q2 2026 close of Corstasis acquisition. U.S. launch will leverage existing cardiovascular salesforce; ex-U.S. expansion planned post-commercialization.
- **Triple Combo Potential**: Market research shows high physician interest in 70% LDL reduction; label likely to reference bempedoic acid and statin efficacy without outcomes data.
- **Guideline Impact**: U.S. dyslipidemia guidelines expected Q1 2026, with harmonization with European guidelines emphasizing bempedoic acid's role in statin-intolerant patients.
- **Risk Management**: No concessions anticipated; payers prioritize outcomes (e.g., CLEAR Outcomes study) over price, differentiating Esperion from competitors without outcomes data.
- **Salesforce Expansion**: Modest expansion for Enbumyst launch; long-term capacity to carry 2-4 products based on call point overlap and life cycle stage.

Esperion Therapeutics, Inc. (ESPR) Q4 2025 Earnings Call Transcript

- **Revenue Surge**: Total revenue up 69% YoY to $87.3M, driven by U.S. net product (+31% YoY) and collaboration (+128% YoY). 
- **Pipeline Breakthrough**: ESP-2001 PSC trial set for Q1 2026 IND filing. 
- **Japan Expansion**: Otsuka launch imminent; Daiichi Sankyo Europe royalty growth 21% QoQ. 
- **Gross Margin Turnaround**: 2026 tech transfer to DSE to drive margin expansion. 
- **Reimbursement Efficiency**: Medicare approval rate 87%, commercial 86%, with co-pay reductions of 47% YoY.

**【CEO Opening Remarks】**
- Total revenue for Q3 2025 grew 69% YoY to $87.3 million, driven by U.S. net product revenue of $40.7 million (+31% YoY) and collaboration revenue of $46.7 million (+128% YoY). 
- Bempedoic acid products (NEXLETOL/NEXLIZET) saw 9% sequential growth in retail prescriptions, with 30,000+ prescribers now onboarding. 
- International expansion highlighted by Japan's preliminary pricing approval for NEXLETOL and NEXLIZET, and European partnerships (Daiichi Sankyo Europe, Otsuka Pharmaceutical) driving 21% sequential royalty growth. 
- Pipeline advancement: ESP-2001 for primary sclerosing cholangitis (PSC) entered IND-enabling studies, targeting Q1 2026 first-in-human trial.

**【CFO Financial Commentary】**
- GAAP net income of $420 million, Non-GAAP EPS exceeded expectations at $1.00. 
- R&D expenses rose 36% YoY to $14.1 million, SG&A increased 5% to $41.8 million due to litigation and media costs. 
- $75 million equity offering in Q3 to support strategic initiatives, maintaining full-year 2025 operating expense guidance of $215-$235 million.

**【Q&A Highlights】**
- **Gross Margin Progression**: Tech transfer to Daiichi Sankyo Europe expected to begin Q1 2026, driving 2026 gross margin improvement. 
- **Japan Launch Timing**: Otsuka's NEXLETOL/NEXLIZET expected to launch within 2-3 weeks of final pricing approval, targeting Japan's 3rd-largest lipid market. 
- **Pipeline Momentum**: ESP-2001 PSC trial enrollment planning with FDA, prioritizing centers with high PSC prevalence. 
- **Reimbursement Trends**: Medicare approval rate improved to 87% (from 86% Q2), with $29 co-pay for 30-day supply vs. $64 Q1. 
- **340B Impact**: Minimal (negligible) impact on U.S. revenue, no material effect on 2026 outlook.

Esperion Therapeutics, Inc. (ESPR) Q3 2025 Earnings Call Transcript

- **Revenue Milestone**: First quarter of operating income ($15M) achieved, with $82.4M total revenue (+12% YoY).
- **Market Momentum**: U.S. prescriptions up 42% YoY, 28,000 prescribers, and 600K+ digital campaign interactions.
- **Global Expansion**: 500K+ European patients treated; Japan approval and $120M milestone payments expected Q4 2025.
- **Pipeline Strength**: PSC program IND filing in H2 2026; triple combo product development on track.
- **Profitability Path**: Transition to sustainable profitability by Q1 2026 with $215-235M operating expense guidance.


**【CEO Summary Section】**
- **Revenue Growth**: Total revenue reached $82.4 million (12% YoY), with U.S. net product revenue up 42% YoY to $40.3 million. Operating income from ongoing business was $15 million, marking the first quarter of profitability.
- **Market Adoption**: U.S. prescriptions grew 15% sequentially, driven by digital campaigns (e.g., "Can't take a statin? Make NEXLIZET happen") and a 23% share of prescriptions from digital-only touchpoints. Prescriber base expanded to 28,000 HCPs.
- **International Expansion**: European partner Daiichi Sankyo Europe (DSE) surpassed 500,000 treated patients. Japan approval expected Q4 2025 with $120M milestone payments. Canada and Israel approvals pending Q4 2025 and H1 2026, respectively.
- **Pipeline Progress**: Triple combination product development on track. PSC program IND filing expected H2 2026 with $1B market potential. Intellectual property strengthened with 2040 generic launch agreements.

**【CFO Financial Commentary】**
- **Financial Health**: Cash of $86.1 million supports growth. R&D expenses down 37% YoY to $7.2 million; SG&A down 11% to $39.5 million, driven by reduced media costs.
- **Profitability Path**: Transition to sustainable profitability expected Q1 2026. Full-year 2025 operating expenses guided at $215-235 million, including $15M non-cash stock comp.
- **Collaboration Revenue**: $42.1 million (7% YoY decline due to one-time DSE milestone), but +105% growth excluding this milestone.

**【Q&A Key Highlights】**
- **Prior Auth Dynamics**: Over 80% approval rates, with CVS/Aetna at 93-94%. Digital campaigns drove 600K+ website visits and 1/4 prescriptions from digital-only HCPs.
- **Tech Transfer Impact**: Inventory reduction starting Q4 2025 as DSE ramps up manufacturing, improving gross margins in 2026.
- **Competitive Position**: Unique primary prevention indication and statin-intolerant patient focus differentiate NEXLETOL/NEXLIZET. No future oral non-statin competitors have outcome studies in primary prevention.
- **Growth Drivers**: Medicare out-of-pocket improvements, TV ad launch in late 2025, and consumer-driven demand (patients asking for the drug).
- **Pipeline Confidence**: PSC program on track for IND filing. Triple combo product aims to rival injectables with oral convenience.


Esperion Therapeutics, Inc. (ESPR) Q2 2025 Earnings Call Transcript

- **US Sales Acceleration**: Q1 2025 US revenue up 41% YoY to $34.9M, with Q2 scripts 8% higher than Q1.
- **Global Expansion Momentum**: 472,500 European patients treated; Japan launch on track for H2 2025.
- **Innovative Pipeline**: Triple combo therapy targeting >60% LDL reduction set for 2027 launch; ACLY inhibitor for rare liver disease PSC advancing.
- **Financial Strength**: $114.6M cash balance; 2025 operating expenses guided at $215-235M.

**【CEO Business Overview】**
- **US Market Growth**: Q1 2025 US net product revenue reached $34.9 million, up 41% YoY, driven by expanded labeling and commercial initiatives. Q1 script growth was 2% sequential, with Q2 early trends showing 8% YoY growth.
- **International Expansion**: Partner Daiichi Sankyo Europe achieved 472,500 European patients treated as of Q1. Otsuka Pharmaceutical's Japan launch is on track for H2 2025, targeting the world's 3rd largest CVD market. Canada approvals expected Q4 2025.
- **Pipeline Advancement**: ACLY inhibitor for PSC declared lead indication; triple combination therapy targeting >60% LDL reduction through bempedoic acid + ezetimibe + statin, with 2027 commercialization goal.

**【CFO Financial Highlights】**
- **Revenue Performance**: Total Q1 2025 revenue $65 million (63% YoY growth excluding one-time 2024 milestone). US product revenue $34.9 million (+41% YoY). Collaboration revenue $30.1 million (+97% YoY excluding milestone).
- **Cost Management**: R&D expenses $12.6 million (-6% YoY). SG&A $43 million (+2% YoY) due to marketing investments. Cash balance $114.6 million as of March 31, 2025.
- **Guidance**: Full year 2025 operating expenses $215-235 million, including $15 million non-cash stock comp.

**【Q&A Key Takeaways】**
- **BD Strategy**: No set timeline for new deals; prioritize strategic fit over timing. Otsuka milestones not required for new partnerships.
- **Triple Combo Value**: 60-70% LDL reduction in one pill vs. 2-pill regimens. 2027 launch targeting high efficacy with convenience.
- **Seasonality Impact**: Q1 2025 faced record Medicare confusion and deductible resets, but Q2 growth already outpacing Q1.
- **Gross Margin Outlook**: Improving with DSE tech transfer; expect normalization to biotech levels over next 1-2 years.

Esperion Therapeutics (ESPR)-6 May 25-2025 Q1 Earnings call transcript

- **Revenue Surge**: Q4 2024 revenue up 114% YoY to $69.1M, driven by U.S. net product (+52%) and collaboration (+227%) growth.
- **Triple Therapy Breakthrough**: Developing triple combo with statins for >60% LDL-C reduction, avoiding CVOT requirement.
- **Global Expansion**: Japan, Australia/New Zealand, Israel partnerships to expand access, with DSE treating 453,000 patients in Europe.
- **Financial Resilience**: $144.8M cash, reduced OpEx guidance ($215-235M), and smoothed Medicare impact for 2025 growth.

**【CEO Summary Section】**
- **Transformational Year 2024**: Received FDA expanded labels for NEXLETOL and NEXLIZET, enabling LDL-C reduction in primary and secondary prevention patients. Achieved 12% sequential growth in Total Retail Prescription Equivalents (TRPEs) to 173 million covered lives and 25,000 prescribers.
- **Triple Combination Product**: Developing bempedoic acid-based triple therapy with statins for LDL-C reduction exceeding 60%, targeting cardiovascular prevention without requiring a CVOT.
- **Global Expansion**: Partnered with Otsuka for Japan (JNDA submission Q2 2025), CSL Seqirus for Australia/New Zealand, and Neopharm Israel for Middle East. European partner DSE treated 453,000 patients, up 19% QoQ.
- **Clinical Momentum**: Presenting post-hoc analyses at ACC 2025 and advancing R&D pipeline with ACLY inhibitors for rare cardiometabolic diseases.

**【CFO Financial Commentary】**
- **Q4 2024 Financials**: Total revenue $69.1M (+114% YoY), U.S. net product revenue $31.6M (+52% YoY), collaboration revenue $37.6M (+227% YoY). R&D expenses down 38% to $11M, SG&A down 19% to $36.9M.
- **Balance Sheet Strength**: $144.8M cash as of Dec 31, 2024. Repaid $210M convertible debt, reducing interest expense. 2025 OpEx guidance: $215-235M.
- **Gross-to-Net Smoothing**: Medicare coverage gap removal in 2025 to align revenue growth with TRPEs, reducing Q4 2024 impact.

**【Q&A Highlights】**
- **Triple Combo Strategy**: FDA discussions ongoing; no CVOT required. Potential patent extension via composition-of-matter claims. Field feedback shows prescribers prioritizing NEXLIZET over ezetimibe/statin combos.
- **Sales Force Efficiency**: 20,000 HCPs covered; digital engagement driving consumer activation. Q1 2025 slower due to deductible resets, but March momentum expected.
- **International Growth**: DSE royalties up 116% YoY to $32.6M. Otsuka JNDA submission milestone driven $9.7M Q4 royalty. Health Canada NDA filed for Canada launch Q4 2025.
- **Pipeline Ambitions**: R&D Day (April 24) to announce lead indication for ACLY inhibitors targeting rare liver/kidney diseases.

Actual									-2.84	4.32	-3.07	-3.89	-3.5	-1.67	-2.62	-1.77	-0.93	-1.05	-0.81	-0.76	-0.79	-0.46	-0.37	-0.5	0.34	-0.33	-0.15	-0.11	-0.21	-0.02	-0.16	0.22
Forecast									-3.2959	1.6456	-3.5225	-3.7601	-2.5169	-1.8434	-2.8048	-2.2693	-1.0358	-0.9289	-0.9251	-0.8485	-0.652	-0.6114	-0.4281	-0.4817	0.0487	-0.1721	-0.1753	-0.1486	-0.1548	-0.1457	-0.0783	0.2433
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+13.83%	+162.52%	+12.85%	-3.45%	-39.06%	+9.41%	+6.59%	+22.00%	+10.21%	-13.04%	+12.44%	+10.43%	-21.17%	+24.76%	+13.57%	-3.80%	+598.15%	-91.75%	+14.43%	+25.98%	-35.66%	+86.27%	-104.34%	-9.58%

ESPR

ESPR fundamentals

ESPR Q4 2025 Earnings

Earnings Call

You can ask Aime

ESPR

ESPR fundamentals

ESPR Q4 2025 Earnings

Earnings Call

ESPR Earnings Call Summary for Q4/20258:00 AM on Mar 10, 2026

ESPR Earnings Call Summary for Q3/20258:00 AM on Nov 6, 2025

ESPR Earnings Call Summary for Q2/20258:00 AM on Aug 5, 2025

ESPR Earnings Call Summary for Q1/20258:00 AM on May 6, 2025

ESPR Earnings Call Summary for Q4/20248:00 AM on Mar 4, 2025

You can ask Aime